Inocras & Broad Institute Unveil New TCGA Whole-Genome Insights to Advance Cancer Genomics
Researchers from Inocras and the Broad Institute of MIT and Harvard are set to unveil significant new findings from one of the most extensive whole-genome cancer analyses to date, marking a major step forward in the field of cancer genomics. The results will be presented at the AACR Annual Meeting 2026 in San Diego, highlighting how large-scale genomic data can accelerate discovery and reshape precision oncology.
This collaborative effort centers on the comprehensive analysis of whole-genome sequencing (WGS) data generated by the The Cancer Genome Atlas (TCGA), a landmark initiative that has driven cancer research for over two decades. Drawing from more than 8,000 tumor-normal whole-genome pairs across over 30 distinct cancer types, the dataset represents one of the largest and most detailed resources of its kind. In total, the analysis includes over 250 million harmonized variant calls, offering an unprecedented view into the genetic complexity of cancer.
For years, much of cancer genomics research has relied on whole-exome sequencing (WES), which focuses only on the protein-coding regions of the genome—approximately 1–2% of the total DNA. While WES has enabled many important discoveries, it leaves the vast majority of the genome unexplored. This includes noncoding regions that play critical roles in gene regulation, chromosomal structure, and mutation patterns. By shifting to whole-genome sequencing, the Inocras–Broad collaboration opens the door to a far more comprehensive understanding of cancer biology.
A key feature of this initiative is the rigorous harmonization and benchmarking of genomic data. The TCGA WGS dataset was analyzed using two independent variant-calling pipelines developed by Inocras and the Broad Institute. These pipelines were applied in parallel, and the results were consolidated into a single, frozen dataset as of December 1, 2025. This “analysis freeze” ensures consistency, reproducibility, and high-quality variant calls, providing a reliable foundation for downstream research and computational modeling.
The resulting dataset is not only vast but also exceptionally well-curated, making it ideal for training advanced artificial intelligence (AI) models. As AI continues to play a growing role in biomedical research, access to high-quality, large-scale datasets becomes increasingly important. The Inocras–Broad collaboration aims to leverage this dataset to support the development of AI-driven tools that can identify novel cancer drivers, predict disease progression, and guide personalized treatment strategies.
The analysis has already yielded a wide range of important insights into the genomic landscape of cancer. Across all tumor samples, researchers identified more than 250 million variants, including over 1 million somatic structural variants (SVs). These findings significantly expand the catalog of known genetic alterations associated with cancer.
One of the most notable advances is the identification of new candidate driver mutations in both coding and noncoding regions of the genome. While traditional studies have focused primarily on mutations within genes, this analysis highlights the importance of mutations in regulatory regions such as promoters and enhancers. These noncoding alterations can have profound effects on gene expression and tumor behavior, yet they have historically been difficult to detect and interpret.
In addition to new driver mutations, the study reveals previously unrecognized patterns of chromosomal instability. These include novel genomic signatures that may help explain how cancers evolve and adapt over time. Researchers also identified new somatic copy number alterations affecting regulatory elements, further emphasizing the importance of noncoding DNA in cancer development.
The analysis also sheds light on genomic regions that have been relatively understudied, such as the X and Y chromosomes. By examining these chromosomes in detail, the researchers uncovered new patterns of alteration that may contribute to cancer risk and progression in ways that are not yet fully understood.
Another significant finding involves germline variants—genetic changes inherited from a person’s parents. The data show that approximately 10% of all cases contain pathogenic or likely pathogenic germline variants in known cancer predisposition genes. This underscores the importance of considering inherited genetic risk alongside somatic mutations when studying cancer and developing treatment strategies.
The scale and depth of this dataset also enable more accurate assessment of genome ploidy and structural rearrangements, both of which are key features of cancer genomes. By integrating multiple types of genomic information, the researchers can build a more complete picture of tumor biology, helping to identify new therapeutic targets and biomarkers.
According to the principal investigators leading the collaboration, this work represents a major step toward setting a new standard in cancer genomics. By moving beyond the limitations of exome sequencing and embracing the full complexity of the genome, researchers can gain deeper insights into the mechanisms that drive cancer.
Equally important is the collaborative nature of the project. The partnership between Inocras and the Broad Institute reflects a shared commitment to open, rigorous science and large-scale data sharing. By combining expertise in bioinformatics, genomics, and computational biology, the teams have created a resource that will benefit the broader research community.
Looking ahead, the dataset is expected to serve as a critical foundation for future studies in cancer research and precision medicine. Its applications extend beyond basic discovery to include clinical translation, where insights from genomic data can inform diagnosis, prognosis, and treatment decisions.
The integration of AI with whole-genome data is particularly promising. With access to such a rich dataset, researchers can train machine learning models to detect subtle patterns and associations that would be difficult to identify using traditional methods. These models could ultimately lead to more accurate predictions of treatment response and better outcomes for patients.
The findings from this collaboration will be formally presented during an Exhibitor Spotlight session titled “TCGA and Beyond: Whole-Genome Data Powering the Next Era of Cancer Intelligence” at the AACR Annual Meeting 2026. The session will provide an opportunity for researchers to share detailed results, discuss methodological approaches, and outline future directions for the project.
In summary, the Inocras–Broad collaboration represents a significant milestone in cancer genomics. By harnessing the power of large-scale whole-genome data and advanced analytics, the initiative is paving the way for a new era of discovery. From identifying novel driver mutations to enabling AI-driven insights, the work has the potential to transform how cancer is studied and treated, bringing the field closer to truly personalized medicine.
About Inocras
Inocras is a bioinformatics-led company redefining precision health through whole genome data and proprietary analytics. Our oncology and rare disease platforms integrate comprehensive whole genome data with advanced automation to deliver curated and actionable insights at scale that accelerate discovery and diagnostics to improve patient care, bringing a real-world impact. Inocras operates a CLIA/CAP-certified laboratory and partners with leading hospitals, pharmaceutical companies, and research institutions worldwide.
“The Exhibitor Spotlight Theater is a promotional activity and is not approved for continuing education credit. The content of this Exhibitor Spotlight Theater are the opinions of the presenter and do not represent the position or the opinion of the American Association for Cancer Research® (AACR) or its members.” “Not affiliated with or endorsed by AACR.”
